Daniel W. Rosenberg

My laboratory has a longstanding interest in the molecular events that accompany early gastrointestinal neoplasia. We apply powerful and exquisitely sensitive cutting-edge technologies to understand the earliest cellular changes that precede cancer, including RNA-sequencing, computational biology, analysis of the microbiome, proteomics, epigenomics, metabolomics and basic aspects of cell biology (confocal imaging, imaging mass cytometry, organoid culture systems). We are also actively developing mouse genetic models to recapitulate human neoplasia, with a focus on colorectal cancer and inflammatory bowel disease. A major effort of our laboratory is to develop natural products that may be used to interrupt the processes of cancer initiation and progression. We are currently about to launch a large clinical trial to evaluate the benefits of plant-derived phytochemicals on cancer risk using pre and probiotics and personalized nutrition, a study that will involve extensive microbiome analysis in collaboration with investigators at the Jackson Laboratory for Genomic Medicine. This work will incorporate detailed bioinformatics and computational biology, as well as metabolomics and genomics analysis. In summary, we are deeply committed to developing novel strategies to prevent cancer, using natural products and personalized nutritional approaches. The work of our laboratory is highly collaborative, bridging the fields of cancer biology, stem cells, organoid culture systems, tumor immunology, epigenetics, metaboloimcs, genomics and the microbiome.

[2026] The effect of walnut consumption on the peripheral blood mononuclear cell transcriptome. [2025] Epigenetic Modulation, Intratumoral Microbiome, and Immunity in Early-Onset Colorectal Cancer. [2025] Differential susceptibility to colonic ulceration in mice with genetic deletion of Prostaglandin E synthase. [2025] Systemic inflammation and the inflammatory context of the colonic microenvironment is improved by urolithin A. [2024] Correlation between intestinal microbiota and urolithin metabolism in a human walnut dietary intervention. [2023] Combination of naproxen and a chemically-stable eicosapentaenoic acid analog provide additive tumor protection in Pirc rats.